

Kum Cheun (KC) is Head of Asia Pacific Regulatory & Development Policy for Novartis, leads in the development of regulatory and development policy, and regulatory intelligence for Asia Pacific. He is Co-Chair of Singapore Association of Pharmaceutical Industries (SAPI) Regulatory Affairs Committee, Chair of EFPIA ASEAN Regulatory Network. He was Co-Chair of the ASEAN Pharmaceutical Research Industry Association (APRIA) and active member of EFPIA International Regulatory Expert Group (IREG), EFPIA regional regulatory networks (India, Korea-Taiwan), DIA Steering Committee of Singapore, DIA Asia Labelling Community member, ISPE Asia Pacific Focus Group, Steering Committee of Asia Partnership Conference of Pharmaceutical Associations (APAC), member of APAC RA-EWG, member of Asia Partnership Conference of Regenerative Conference (APACRM) and Centre of Regulatory Excellence (CoRE) Duke-NUS Visiting Expert.

KC was former Drug Registration Branch's Deputy Head responsible for the 'Quality Evaluation and Submissions Section' of the Centre for Drug Administration at the Singapore Health Sciences Authority (HSA). In HSA he was involved in the development of product registration guidance such as the Variation Guideline and BA/BE Guideline, participated in the ASEAN Harmonization of Pharmaceutical Products guideline discussion and was Co-Lead in developing the ASEAN Process Validation Guideline.